Skip to main content
TipRanks
Go Ultimate75% OFF

Globus Medical (GMED) Stock Price & Analysis

1,028 Followers

GMED Stock Chart & Stats

$66.89-$1.71(-2.49%)
At close: 4:00 PM EST
$70$75$80$85Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$66.63 - $69.54
52-Week Range
$66.63 - $101.40
Previous Close
$68.60
Volume
N/A
Average Volume (3M)
1.80M
Market Cap
$9.09B
Enterprise Value
$9.78B
Total Cash (Recent Filing)
$517.43M
Total Debt (Recent Filing)
$107.55M
Price to Earnings (P/E)
16.2
Beta
0.74
Next Earnings
Feb 23, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet

Very low leverage gives Globus Medical substantial financial resilience and flexibility. The company can fund product development, technology investments and potential strategic actions without relying heavily on debt, while stronger equity supports stability through operating volatility.

Strong Cash Generation

Robust operating and free cash flow indicate strong earnings quality and meaningful internal funding capacity. This supports continued innovation, commercial investment and shareholder returns while reducing dependence on external financing during periods of slower revenue growth.

Technology And Product Expansion

Rapid adoption of enabling technologies can deepen Globus’s role in surgical workflows and support recurring procedure-related demand. Greater installed-base utilization also creates a platform for future implant growth, technology attachments and differentiated clinical offerings.

Bears Say

Revenue Growth Deceleration

The reduced outlook signals that near-term growth is below prior expectations, limiting confidence in the pace of expansion over the next several quarters. Delayed Spine launches and weaker Nevro performance also make the consolidated revenue trajectory less predictable.

Nevro Revenue Weakness

Persistent Nevro revenue and trial-volume weakness is a material drag on consolidated performance. Recovery depends on rebuilding sales productivity and procedure adoption, creating execution risk even though management reported improving Nevro profitability.

Competitive Pricing Pressure

Ongoing biologics pricing competition can constrain revenue realization and make margin improvement harder to sustain in that product area. The company’s effort to increase attachment rates may help volume, but it does not remove the structural pressure on pricing.

Globus Medical News

GMED FAQ

What was Globus Medical’s price range in the past 12 months?
Globus Medical lowest stock price was $66.63 and its highest was $101.40 in the past 12 months.
What is Globus Medical’s market cap?
Globus Medical’s market cap is $9.09B.
When is Globus Medical’s upcoming earnings report date?
Globus Medical’s next earnings report is estimated for Feb 23, 2027 (not yet confirmed), which is in 93 days.
How were Globus Medical’s earnings last quarter?
Globus Medical released its earnings results on Nov 05, 2026. The company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.197 by $0.033.
Is Globus Medical overvalued?
According to Wall Street analysts Globus Medical’s price is currently Undervalued.
Does Globus Medical pay dividends?
Globus Medical does not currently pay dividends.
What is Globus Medical’s EPS estimate?
Globus Medical’s EPS estimate is 1.29.
How many shares outstanding does Globus Medical have?
Globus Medical has 110,041,595 shares outstanding.
What happened to Globus Medical’s price movement after its last earnings report?
Globus Medical reported an EPS of $1.23 in its last earnings report, beating expectations of $1.197. Following the earnings report the stock price went down -12.758%.
Which hedge fund is a major shareholder of Globus Medical?
Hedge funds hold Globus Medical shares: the largest hedge-fund position in Globus Medical is 72,325,182 shares, and hedge funds increased their holdings by 59.1K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology